Claims for Patent: 7,776,618

Summary for Patent: 7,776,618

Title:	Diagnostic detection device
Abstract:	The invention comprises a device for detecting an analyte in a liquid sample deposited on a first portion of the device for transport to a second portion of the device that is in fluid contact with the first portion. In specific embodiments, the device comprises a labeled conjugate comprising a binding member reactive with a first epitope of the analyte and a label comprising a gold colloid, preferably having a mean particle size of 50 nm to 100 nm. In further embodiments, the device comprises a capture component comprising polymerized streptavidin. The diagnostic device is particularly useful in the preparation of pregnancy test kits.
Inventor(s):	Nazareth; Albert (Mercerville, NJ), Snowden; Timothy (Howell, NJ), Cheng; Yea-shun (Doylestown, PA)
Assignee:	Church & Dwight Co., Inc. (Princeton, NJ)
Application Number:	11/681,061
Patent Claims:	1. A device for detecting an analyte in a liquid sample deposited on a first portion of the device for transport to a second portion of the device, wherein the device comprises a biphasic substrate comprising: A) a release medium formed of a first material and comprising: i) a labeled conjugate comprising a binding member reactive with a first epitope of the analyte and a label comprising colloidal gold particles having a mean particle size of at least about 50 nm prior to formation of the labeled conjugate; and ii) a biotinylated capturable component having a site reactive with a second epitope of the analyte, such that if the analyte is present in the sample, a complex is formed comprising the gold colloid labeled conjugate, the analyte for detection, and the biotinylated capturable component; and B) a capture medium in fluid communication with the release medium and formed of a second, different material, the capture medium comprising a capture site for capturing the complex, the capture site having immobilized thereon a capture component comprising polymerized streptavidin. 2. The device of claim 1, wherein the colloidal gold particles have a mean particle size of about 50 nm to about 100 nm. 3. The device of claim 1, wherein the colloidal gold particles have a mean particle size of about 55 nm to about 85 nm. 4. The device of claim 1, wherein the colloidal gold particles have a mean particle size of about 60 nm to about 75 nm. 5. The device of claim 1, wherein greater than 50% by weight of the polymerized streptavidin is at least about 100 kDa in size. 6. The device of claim 1, wherein the release medium and the capture medium are in a non-overlapping fluid communication. 7. The device of claim 1, wherein the release medium and the capture medium are in overlapping fluid communication. 8. The device of claim 1, wherein the capture component is immobilized to the capture medium through direct attachment of the polymerized streptavidin to the capture medium. 9. The device of claim 1, wherein the capture component is immobilized to the capture medium through indirect attachment of the polymerized streptavidin to the capture medium. 10. The device of claim 9, wherein the indirect attachment is through a synthetic intermediate material. 11. The device of claim 10, wherein the synthetic intermediate material comprises latex beads. 12. The device of claim 9, wherein the indirect attachment is through a natural intermediate material. 13. The device of claim 12, wherein the natural material comprises a protein selected from the group consisting of immunoglobulins, bovine serum albumin, and combinations thereof. 14. The device of claim 1, wherein the analyte comprises human chorionic gonadotropin (hCG). 15. The device of claim 1, wherein the analyte comprises leuteinizing hormone (LH). 16. The device of claim 1, wherein the analyte comprises follicle stimulating hormone (FSH). 17. A method for determining the presence of an analyte in a liquid sample comprising: A) providing a device for detecting an analyte in a liquid sample deposited on a first portion of the device for transport to a second portion of the device, wherein the device comprises a biphasic substrate comprising: 1) a release medium formed of a first material and comprising: i) a labeled conjugate comprising a binding member reactive with a first epitope of the analyte and a label comprising colloidal gold particles having a mean particle size of at least about 50 nm prior to formation of the labeled conjugate; and ii) a biotinylated capturable component having a site reactive with a second epitope of the analyte, such that if the analyte is present in the sample, a complex is formed comprising the gold colloid labeled conjugate, the analyte for detection, and the biotinylated capturable component; and 2) a capture medium in fluid communication with the release medium and formed of a second, different material, the capture medium comprising a capture site for capturing the complex, the capture site having immobilized thereon a capture component comprising polymerized streptavidin; B) adding a liquid sample to the first portion of the device; C) allowing the liquid sample to flow across the release medium and the capture medium; and D) determining the presence of the analyte in the liquid sample by visual inspection of the capture medium, wherein the presence of the analyte is indicated by the presence of color development at the capture site caused by the binding of the streptavidin capture component with the complex formed of the gold colloid labeled conjugate, the analyte for detection, and the biotinylated capturable component. 18. The method of claim 17, wherein the analyte comprises human chorionic gonadotropin (hCG). 19. The method of claim 17, wherein the analyte comprises leuteinizing hormone (LH). 20. The method of claim 17, wherein the analyte comprises follicle stimulating hormone (FSH).

Details for Patent 7,776,618

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	7,776,618	2027-03-01
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	7,776,618	2027-03-01
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	7,776,618	2027-03-01